CSF1R and tenosynovial giant cell tumor, diffuse type: Reduction of CD14dimCD16+ monocytes was shown in the PB of patients with glioblastoma treated with the highly selective CSF1R inhibitor PLX3397 [21] and of patients with diffuse-type giant cell tumor treated with the anti-CSF1R antibody RG7155 [42].